AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
AbbVie may have been second to the preventative migraine market after Biohaven’s Nurtec ODT, but the Big Pharma is getting prescribers onside. That’s according to a new report and analysis from Spherix, which found that Qulipta—approved last September—is already racing to catch up with Nurtec, which gained its second approval in May 2021 as a preventive […]
Incyte’s eczema cream Opzelura off to ‘very successful’ launch despite FDA warning: CEO
When Incyte’s Jakafi sister med Opzelura entered the atopic dermatitis market with unexpected FDA safety warnings, industry watchers worried doctors would balk at prescribing the cream. But early results suggest that’s not the case, and one analyst figures the drug could double the Street’s 2022 sales expectations…
Robust Uptake of AbbVie’s Qulipta Turns Up the Pressure for Amgen, Eli Lilly, and Teva in the Prevention Segment of the Migraine Market, Spherix Reports
Needle aversion and oral therapy preference is costing new prescription opportunities for Amgen’s Aimovig, Eli Lilly’s Emgality, and Teva’s Ajovy EXTON, Pa., February 8, 2022 / PRNewswire/ — The September 2021 approval of Qulipta for the preventive treatment of episodic migraine has added a third asset to AbbVie’s (formerly Allergan’s) migraine portfolio. While most of […]
Neurologists pass on Aduhelm again. Most agree with CMS decision to limit coverage, study finds
A majority of neurologists agree with Medicare on the need for more data on Biogen and Eisai’s Alzheimer’s disease med Aduhelm, despite FDA approval. More than half (52%) of neurologists agree with the Centers for Medicare and Medicaid Services (CMS)…
Spherix Global Insights Embarks on Its Fifth Year of Extensive ADPKD Coverage as the Market Heats Up
Armed with fresh insights from their patient chart audit, Spherix focuses on market trending and evolving perceptions of pipeline agents for ADPKD EXTON, Pa., February 3, 2022 /PRNewswire/ — Autosomal dominant kidney disease (ADPKD) is a life-threatening genetic disease that causes fluid-filled cysts to develop and enlarge in both kidneys. With only one FDA-approved treatment (Otsuka’s […]
CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say
Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s controversial Alzheimer’s disease drug, Aduhelm, to Medicare patients enrolled in approved clinical trials only. In fact, half of those surveyed said CMS’ decision would hit how they prescribe the rival […]
Neurologists React to CMS’ Proposed NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease in the Latest from Spherix Global Insights
Insights capture the potential impact of the proposed NCD decision on Biogen/Eisai’s Aduhelm, Eli Lilly’s donanemab, Eisai/Biogen’s lecanemab, and Roche/Genentech’s gantenerumab EXTON, Pa., January 27, 2022 / PRNewswire/ — On January 11th, the Centers for Medicare and Medicaid Services (CMS)’ proposed Medicare reimbursement of FDA-approved anti-amyloid monoclonal antibodies (mAbs) be limited to clinical trials under […]
MarketingRx roundup: Aduhelm can’t get traction with docs; Pfizer presses vaccine effort during NFL playoffs
While much of the pharma industry’s attention pivoted to CMS’ preliminary decision last week to only cover Biogen’s controversial Alzheimer’s drug Aduhelm in clinical trials and its effect on prescribing, neurologists were already hesitant. Spherix Global Insights has been tracking neurologists’ perception of Aduhelm…
Efficacy Expectations for Refractory Migraine Patients are Vital for Strong Uptake of Impel’s Trudhesa, Spherix Reports
New research suggests Trudhesa is more likely to compete with Biohaven’s Nurtec ODT, AbbVie’s Ubrelvy, and Eli Lilly’s Reyvow over dihydroergotamine mesylate formulations for new prescriptions EXTON, Pa., January 13, 2022 / PRNewswire/ — Impel’s new entrant into the acute migraine landscape, the dihydroergotamine mesylate (DHE) nasal spray, Trudhesa, is off to a somewhat light […]
Susquehanna Private Capital Announces Investment in Spherix Global Insights
Susquehanna Private Capital (“SPC”), a middle market private equity firm, today announced an investment in Spherix Global Insights (“Spherix” or the “Company”), a leading pharmaceutical market insights firm focused on the dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology specialties. Terms of the transaction were not disclosed… (read more)
